REG - ReNeuron Group plc - Block Listing Review and Total Voting Rights

ReNeuronAnnouncement

01/09/2022 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220901:nRSA8348Xa&default-theme=true

RNS Number : 8348X  ReNeuron Group plc  01 September 2022

 

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Block Listing Review

and Total Voting Rights

 

ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome
technologies, provides the following update in accordance with Schedule Six of
the AIM Rules for Companies regarding its existing block listing arrangements.

 

 Name:                                                                          ReNeuron Group plc
 Name of Scheme:                                                                ReNeuron Share Option Schemes
 Period of Return:                                                              From 1 March 2022 to 31 August 2022
 Balance of unallotted securities under scheme(s) from previous return:         3,455,769 Ordinary Shares (of 1p each)

 Plus: The amount by which the block scheme(s) has been increased since the     -
 date of the last Review (if any increase has been applied for):
 Less: Number of securities issued/allotted under scheme(s) during period       82,270
 Equals: Balance under scheme(s) not yet issued/allotted at end of period:      3,373,499 Ordinary Shares
 Number and class of securities originally admitted and the date of admission:  20,000 ordinary shares on 13 May 2010

 

Total Voting Rights

At 31 August 2022, the Company had 57,145,893 Ordinary Shares in issue, each
carrying one voting right.

 

As the Company holds no ordinary shares in treasury, the figure of 57,145,893
may be used by shareholders as the denominator for the calculation by which
they will determine if they are required to notify their interest in, or a
change in their interest in, the Company under the FCA's Disclosure Guidance
and Transparency Rules.

 

ENDS

 

 

 

 

Contacts:

 

 ReNeuron                                          www.reneuron.com/investors (http://www.reneuron.com/investors)
 Iain Ross, Chairman                               Via Walbrook PR
 Catherine Isted, Chief Financial Officer

 Liberum Capital Limited (NOMAD and Joint Broker)  +44 (0)20 3110 2000

 Phil Walker (Investment Banking)

 Richard Lindley (Investment Banking)

 Ben Cryer (Investment Banking)

 Allenby Capital Limited (Joint Broker)            +44 (0)20 3328 5656
 James Reeve/George Payne (Corporate Finance)
 Stefano Aquilino (Sales & Corporate Broking)

 Walbrook PR (Media & Investor Relations)          +44 (0)20 7933 8780 or reneuron@walbrookpr.com
                                                   (mailto:reneuron@walbrookpr.com)
 Paul McManus/Alice Woodings                       +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About ReNeuron

ReNeuron is a UK based leader in proprietary stem cell derived exosome
technologies, harnessing its unique stem cell technologies to develop 'off the
shelf' treatments for diseases with significant unmet needs.

ReNeuron's stem cell derived proprietary exosome technology platform offers a
delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins,
small molecules and genes. The Group has a growing number of partner
collaborations with Global Pharma, Biotech and academic partners in this
fast-expanding area of scientific and commercial interest. ReNeuron also has
the ability, through its conditionally immortalised induced pluripotent stem
cell (iPSC) platform, to make allogeneic tissue cells of choice and has the
potential to produce exosomes with tissue specific targeting ability.

The Group has out-licenced its CTX Programme for stroke disability and hRPC
programme in retinitis pigmentosa to Fosun in China and is looking to
out-license both of these programmes in other territories.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.
For further information visit www.reneuron.com (http://www.reneuron.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRBKDBQABKDBFN